These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

680 related articles for article (PubMed ID: 16128623)

  • 1. Design of wide-spectrum inhibitors targeting coronavirus main proteases.
    Yang H; Xie W; Xue X; Yang K; Ma J; Liang W; Zhao Q; Zhou Z; Pei D; Ziebuhr J; Hilgenfeld R; Yuen KY; Wong L; Gao G; Chen S; Chen Z; Ma D; Bartlam M; Rao Z
    PLoS Biol; 2005 Oct; 3(10):e324. PubMed ID: 16128623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs.
    Anand K; Ziebuhr J; Wadhwani P; Mesters JR; Hilgenfeld R
    Science; 2003 Jun; 300(5626):1763-7. PubMed ID: 12746549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug design targeting the main protease, the Achilles' heel of coronaviruses.
    Yang H; Bartlam M; Rao Z
    Curr Pharm Des; 2006; 12(35):4573-90. PubMed ID: 17168763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
    Báez-Santos YM; St John SE; Mesecar AD
    Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening.
    Xiong B; Gui CS; Xu XY; Luo C; Chen J; Luo HB; Chen LL; Li GW; Sun T; Yu CY; Yue LD; Duan WH; Shen JK; Qin L; Shi TL; Li YX; Chen KX; Luo XM; Shen X; Shen JH; Jiang HL
    Acta Pharmacol Sin; 2003 Jun; 24(6):497-504. PubMed ID: 12791174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of bioinformatics in search for cleavable peptides of SARS-CoV M(pro) and chemical modification of octapeptides.
    Du Q; Wang S; Jiang Z; Gao W; Li Y; Wei D; Chou KC
    Med Chem; 2005 May; 1(3):209-13. PubMed ID: 16787316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment.
    Zhang L; Lin D; Kusov Y; Nian Y; Ma Q; Wang J; von Brunn A; Leyssen P; Lanko K; Neyts J; de Wilde A; Snijder EJ; Liu H; Hilgenfeld R
    J Med Chem; 2020 May; 63(9):4562-4578. PubMed ID: 32045235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular docking identifies the binding of 3-chloropyridine moieties specifically to the S1 pocket of SARS-CoV Mpro.
    Niu C; Yin J; Zhang J; Vederas JC; James MN
    Bioorg Med Chem; 2008 Jan; 16(1):293-302. PubMed ID: 17931870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus.
    Goetz DH; Choe Y; Hansell E; Chen YT; McDowell M; Jonsson CB; Roush WR; McKerrow J; Craik CS
    Biochemistry; 2007 Jul; 46(30):8744-52. PubMed ID: 17605471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease.
    Zhu L; George S; Schmidt MF; Al-Gharabli SI; Rademann J; Hilgenfeld R
    Antiviral Res; 2011 Nov; 92(2):204-12. PubMed ID: 21854807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design.
    Xue X; Yu H; Yang H; Xue F; Wu Z; Shen W; Li J; Zhou Z; Ding Y; Zhao Q; Zhang XC; Liao M; Bartlam M; Rao Z
    J Virol; 2008 Mar; 82(5):2515-27. PubMed ID: 18094151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
    Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD
    J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and activity of an octapeptide inhibitor designed for SARS coronavirus main proteinase.
    Gan YR; Huang H; Huang YD; Rao CM; Zhao Y; Liu JS; Wu L; Wei DQ
    Peptides; 2006 Apr; 27(4):622-5. PubMed ID: 16242214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.
    Chen L; Gui C; Luo X; Yang Q; Günther S; Scandella E; Drosten C; Bai D; He X; Ludewig B; Chen J; Luo H; Yang Y; Yang Y; Zou J; Thiel V; Chen K; Shen J; Shen X; Jiang H
    J Virol; 2005 Jun; 79(11):7095-103. PubMed ID: 15890949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.
    Regnier T; Sarma D; Hidaka K; Bacha U; Freire E; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2009 May; 19(10):2722-7. PubMed ID: 19362479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.
    Dragovich PS; Prins TJ; Zhou R; Webber SE; Marakovits JT; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Ford CE; Burke BJ; Rejto PA; Hendrickson TF; Tuntland T; Brown EL; Meador JW; Ferre RA; Harr JE; Kosa MB; Worland ST
    J Med Chem; 1999 Apr; 42(7):1213-24. PubMed ID: 10197965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
    Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
    Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation.
    Ghosh AK; Takayama J; Rao KV; Ratia K; Chaudhuri R; Mulhearn DC; Lee H; Nichols DB; Baliji S; Baker SC; Johnson ME; Mesecar AD
    J Med Chem; 2010 Jul; 53(13):4968-79. PubMed ID: 20527968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.
    Matthews DA; Dragovich PS; Webber SE; Fuhrman SA; Patick AK; Zalman LS; Hendrickson TF; Love RA; Prins TJ; Marakovits JT; Zhou R; Tikhe J; Ford CE; Meador JW; Ferre RA; Brown EL; Binford SL; Brothers MA; DeLisle DM; Worland ST
    Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11000-7. PubMed ID: 10500114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.